Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group has entered into a lucrative global license agreement with Merck Sharp & Dohme LLC, granting exclusive rights to develop, manufacture, and commercialize its investigational GLP-1 receptor agonist, HS-10535. This deal includes an upfront payment of $112 million, potential milestone payments reaching up to $1.9 billion, and royalties, showcasing Hansoh’s strategic move to leverage its technology platforms for financial growth. The agreement also provides Hansoh opportunities to co-promote or solely commercialize the product in mainland China, Hong Kong, and Macau.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.